Tag Archives: treatment

PAPR Inhibitors May Work Against More Ovarian Cancers

PAPR inhibitors, first used in trials for women with ovarian cancer who had a mutation in the BRCA1 or BRCA2 gene, are now being used in trials for women without … Continue reading 

Posted in News | Also tagged , , , , , | Leave a comment

Chemo Dosing Influences Drug Resistance

A mouse study showed that continuous treatment with docetaxel (Taxotere) showed greater anti-tumor effects than treating the mice once a week or once every three weeks. Additionally, treating less often … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Chemotherapy Drug Shortages include Taxol

Drug shortages around the country are affecting cancer patients. Recently ABC news covered the paclitaxel (brand name: Taxol)  shortage. Many cite the low cost of generic drugs as the cause of … Continue reading 

Posted in News | Also tagged , | Leave a comment

Drug Combination to Treat Cancer Expected to Rise

According to an article in the Wall Street Journal, combinations of drugs to treat cancer will be used more frequently in the future. Many studies presented at the 2011 annual … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

J&J withdraws application with FDA for new ovarian cancer drug

Johnson & Johnson, the owner of rights to Yondelis in the United States, has withdrawn its New Drug Application with the Food and Drug Administration for approval of the drug … Continue reading 

Posted in News | Also tagged | Leave a comment

Cost-Effective Analysis of Bevacizumab for Ovarian Cancer

A study published in the Journal of Clinical Oncology concludes that “[t]he addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer is not cost effective.” The study … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Carbo/Doxil in elderly patients

BACKGROUND: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients <70 … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Phase II Trial of Phenoxodial Complete

INTRODUCTION: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we … Continue reading 

Posted in News | Also tagged , , | Leave a comment

ESAs Linked to Ovarian Cancer Mortality (Medpage)

A study presented at the Society for Gynecologic Oncology annual meeting in March, 2011 showed that women treated with ESAs had higher rates of ovarian cancer recurrence and death. ESAs … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Results of a Third Phase III Trial of Avastin in Ovarian Cancer Released

Genentech, a member of the Roche group, announced that a third Phase III trial of Avastin in ovarian cancer met its endpoint of improvement in progression free survivial.  See the … Continue reading 

Posted in News | Also tagged , | Leave a comment

Ovarian cancer in the elderly patient: are we doing enough?

INTRODUCTION: ovarian cancer is deadly and frequently affects older patients. In the next 20 years, the number of patients over 65 will double, and cancer, including ovarian cancer, will increase … Continue reading 

Posted in News | Also tagged | Leave a comment

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

Background: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian … Continue reading 

Posted in News | Also tagged , | Leave a comment